Induction & maintenance treatment of cytomegalovirus (CMV) retinitis in patients w/ AIDS. Prevention of CMV disease in CMV -ve patients who have received solid organ transplant from a CMV +ve donor.
Adult Active CMV retinitis 900 mg bid for 21 days. Inactive CMV retinitis 900 mg once daily. Prevention of CMV disease in solid organ transplantation 900 mg once daily starting w/in 10 days of transplant & 100 days post-transplant. May be continued until 200 days post-transplant for kidney transplant patients. Induction doseRenal impairment CrCl ≥60 mL/min 900 mg bid, 40-59 mL/min 450 mg bid, 25-39 mL/min 450 mg once daily, 10-24 mL/min 450 mg every 2 days. Maintenance/prevention dose CrCl ≥60 mL/min 900 mg once daily, 40-59 mL/min 450 mg once daily, 25-39 mL/min 450 mg every 2 days, 10-24 mL/min 450 mg twice wkly.
Fetotoxicity. Teratogenic & carcinogenic. May cause temporary or permanent inhibition of spermatogenesis. Severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression & aplastic anemia. Possible risk of developing leucopenia & neutropenia when extending prophylaxis beyond 100 days. Preexisting hematological cytopenia or history of drug-related hematological cytopenia & in patients receiving radiotherapy. Monitor complete blood & platelet counts. Should not be used in dialysis patients. Convulsions. Closely monitor signs of added toxicity when concomitantly used w/ didanosine, zidovudine or substances affecting renal function. Impaired renal function. May affect ability to drive or operate machinery. Women of childbearing potential. Pregnancy & lactation. Childn. Elderly.
J05AB14 - valganciclovir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Sign Out
